Unknown

Dataset Information

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China.


ABSTRACT:

Background

Infliximab was the first approved biologic treatment for moderate to severe Crohn's disease (MS-CD) in China. However, the cost-effectiveness of infliximab maintenance therapy (IMT) for MS-CD relative to conventional maintenance therapy remained unclarified.

Aim

To assess the cost-effectiveness of IMT for MS-CD in Chinese patients from the perspective of Chinese public insurance payer.

Methods

A cohort of MS-CD patients managed in a Chinese tertiary care hospital was created to compare IMT with conventional maintenance therapy (CMT) for clinical outcomes and direct medical costs over a 1-year observation time using conventional regression analyses. A decision-analytic model with the generated evidence was constructed to assess the cost-effectiveness of IMT

SUBMITTER: Shi JH 

PROVIDER: S-EPMC7656205 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature